### Analysis:
**Short-term Implications:**
- **Performance vs. Expectations:** Merck reported strong Q1 2012 results, with revenue growth in each of its major businesses (Human Health, Animal Health, and Consumer Care) and an 8% growth in non-GAAP EPS. The company's performance exceeded some market expectations, particularly in the face of significant headwinds such as patent expirations and pricing pressures.
- **Management Tone:** Executives expressed confidence in the companyâ€™s ability to navigate these challenges and maintain growth. They highlighted the strength of their pipeline and the potential for new product launches, including the recently approved JANUMET XR and the upcoming filings for several other products.
- **Guidance Updates:** The company maintained its 2012 revenue and EPS guidance, indicating stable expectations despite the patent expirations and other challenges. This stability suggests that Merck is well-positioned to manage its near-term risks.
- **External/Macro Influences:** The broader economic uncertainty and healthcare environment were mentioned as challenges, but Merck's focus on innovation and strategic investments was highlighted as a way to mitigate these risks.

**Conclusion:**
Merck's Q1 2012 results and management's optimism suggest a positive outlook for the next 1-2 weeks. The company's ability to maintain growth and manage costs effectively, along with its strong pipeline, should provide support for the stock. However, the stock may still face some volatility due to the ongoing uncertainty in the healthcare sector and the potential impact of patent expirations.

**Rating:**
1